Emesis in dogs: a review

Emesis is a common presenting sign in small animal practice. It requires a rational approach to management that is based upon a sound understanding of pathophysiology combined with logical decision making. This review, which assesses the weight of available evidence, outlines the physiology of the vomiting reflex, causes of emesis, the consequences of emesis and the approach to clinical management of the vomiting dog. The applicability of diagnostic testing modalities and the merit of traditional approaches to management, such as dietary changes, are discussed. The role and usefulness of both traditional and novel anti-emetic drugs is examined, including in specific circumstances such as following cytotoxic drug treatment. The review also examines areas in which common clinical practice is not necessarily supported by objective evidence and, as such, highlights questions worthy of further clinical research.

INTRODUCTION

In October 2006, after a series of meetings, the authors published ‘Approach to the Management of Emesis in Dogs’ (Devauchelle and others 2006), intended as a clinical guide to ‘best practice’ in the management of canine emesis. Statements in these guidelines were developed from published papers, consensus opinion and, where necessary, the authors’ own expert opinions. This review details the evidence and emphasises the opinion from which the guidelines were developed and, by doing so, highlights where evidence is lacking or contradictory.

METHODS

A systematic search of the literature was performed on the sites Google Scholar, Web of Science and PubMed, using the terms ‘vomit*’ or ‘emesis’ AND ‘dog’ or ‘canine’ to identify relevant references. Where primary sources were available (papers published in peer reviewed journals) these are referenced. Where relevant information did not fit the above search terms (e.g. secondary effects of drugs), references were identified in a standard manner. To further quantify the strength of evidence available to support the information provided, individual references used to support statements were classified according the scheme shown in Table 1a and assigned an evidence level (EL). As appropriate to support the text an overall evidence grade (OEG) was given according to the scheme in Table 1b. Where multiple references were available, we attempted to ensure those with the highest evidence level were cited. Where peer-reviewed sources were lacking, statements should be considered the opinion of the authors.

THE EMETIC REFLEX

Emesis is facilitated by a sequence of programmed overlapping and coordinated events which reduce the risks of adverse consequences (such as aspiration of acid stomach contents) whilst achieving elimination. The reflex is controlled within the brainstem by a central pattern generator,
Emesis in dogs

Table 1. Scheme used to grade (a) individual references and (b) overall level of evidence. Adapted from 1

| (a) Study type                                           | Level of evidence (LOE) |
|---------------------------------------------------------|-------------------------|
| Systematic review (with homogeneity) of randomised controlled clinical trials (RCT) | 1a                      |
| Individual RCT (with narrow confidence interval)          | 1b                      |
| All or none                                             | 1c                      |
| Systematic review (with homogeneity) of cohort studies   | 2a                      |
| Individual cohort study (including low quality RCT; for e. g., <80% follow-up) or well-controlled laboratory study | 2b                      |

(Outcomes) Research; Ecological studies

Systematic review (with homogeneity) of case-control studies

Individual case-control study or weak laboratory study

Case-series >50 cases

Case series 20 to 50 cases

Case series <20 cases

Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"

(b) Overall evidence grade (OEG)

| Consistent RCT, cohort study, all or none, decision rule validated in different populations. | A                      |
| Consistent retrospective cohort, exploratory cohort, ecological study, outcomes research, good laboratory study, case-control study, extrapolations from level A studies. | B                      |
| Case-series study or extrapolations from level B studies. | C                      |
| Expert opinion without explicit critical appraisal, or based on physiology, bench research or first principles. | D                      |

*The all or none principle is met when all patients died before the treatment became available, but some now survive on it; or when some patients died before the treatment became available, but none now die on it.

CAUSES OF EMESIS

Experimental studies show that many peripheral stimuli of abdominal structures will initiate emesis in dogs (Lang and Marvig 1989 [2b], Xu and Chen 2008 [2b]). Release of 5-hydroxytryptamine/serotonin (5-HT) from enterochromaffin cells, which have been demonstrated in canine gastric and duodenal mucosa, stimulates vagal afferents via 5-HT, receptors (Fukui and others 1992 [2b], Fukui and others 1993a [2b]). It seems that other pathways and local modulatory signals are also important (Lang and others 1988 [2b], Sanger and Andrews 2006 [3a]). Peripheral emetogenic triggers may be abrogated by bilateral vagotomy, effects which are enhanced when combined with ablation of the greater splanchnic nerves, suggesting more than one signal pathway (Fukui and others 1993b [2b]). Vagal afferents, carrying peripheral emetogenic signals, enter the rostral medulla oblongata and pass via the solitary tract to the nucleus of the solitary tract (Fukuda and Koga 1991 [2b], Koga and Fukuda 1992 [2b]). (OEG B).

The ‘chemoreceptor trigger zone’ of the brainstem has been identified as the area postrema which is located on the dorsal surface of the medulla oblongata adjacent to the caudal end of the fourth ventricle (Chernicky and others 1980 [2b]). This region, lacking a blood-brain barrier, is responsive to circulating emetogens.
A number of receptor types have been noted in the area postrema of the dog including dopamine (Stafanini and Clement-Cormier 1981 [2b]), histamine (Bhargava and others 1976 [2b]) and peptide YY (Leslie and others 1988 [2b]). Numerous chemicals, that can induce emesis when administered systemically, also do so via direct application to the area postrema. These include apomorphine, xylazine, prostaglandins and various hormones and peptides (Briggs and Carpenter 1986 [3b], Carpenter and others 1983 [3b], Carpenter and others 1988 [2b], Hikasa and others 1987 [2b]). Ablation of the area postrema inhibits the emetogenic effects of these substances (Carpenter and Briggs 1986 [2b]). Emetogenic signals from the area postrema excite neurones of the nucleus of the solitary tract in the area subpostrema and, from there, the central pattern generator of the vomiting reflex (Koga and Fukuda 1992 [2b]).

Whilst it is generally accepted that dogs, like humans, can suffer motion sickness which can be therapeutically managed, mechanisms are poorly understood and little studied (Conder and others 2008 [1b], Benchaoui and others 2007 [1b], Boyd 1953 [5]). Ablation of the area postrema was thought to stop emetogenic responses to motion, but later critique suggested that a lack of specificity in ablation may have damaged associated structures, possibly the nucleus of the solitary tract in the area subpostrema and, from there, the central pattern generator of the vomiting reflex (Koga and Fukuda 1992 [2b]). [OEG B].

As well as inputs from peripheral, vestibular and area postrema triggers, stimulation from higher centres has been proposed, presumably co-ordinated in the nucleus tractus solitarius.

Clinical diseases associated with emesis in dogs are summarised (Tables 2-5). In many of these diseases emesis is triggered peripherally and co-ordinated centrally, although there may be concomitant activation of the chemoreceptor trigger zone in some conditions e.g. uraemia. Whilst generally considered a mechanism of protection, vomition of food by bitches is believed to be part of the normal rearing process (Korda 1972 [3b]) [OEG C].

### Table 2. Gastrointestinal disease conditions associated with emesis in the dog

| Process | Reference (LOE) | Overall evidence grade |
|---------|-----------------|------------------------|
| Gastritis | Eosinophilic | 2 (4c) | C |
| | Lymphoplasmacytic | 3 (4c) |
| | Granulomatous | 4 (4c) |
| | Acute | 5 (4c) |
| | Associated with spiral bacteria | 6 (4a) |
| | | 7 (3a) |
| | | 8 (4b) |
| | | 9 (4b) |
| Gastric neoplasia | | 10 (4b) | C |
| | | 6 (4a) |
| | | 11 (4b) |
| Gastric ulceration | Non-steroidal anti-inflammatory drugs (NSAIDs) | 12 (4c) | B |
| | | 13 (3b) |
| | | 14 (4c) |
| Neoplasia | | 15 (4c) | C |
| | | 10 (4b) |
| | | 11 (4b) |
| Metabolic | | 16 (4b) | C |
| Hypergastrinaemia/Other APU-Domas | | 17 (4c) | C |
| | | 18 (4c) |
| | | 19 (4c) |
| Irritant | | 20 (4c) |
| Mastocytosis | | 21 (4b) | C |
| Gastric/intestinal entrapment | Gastric dilatation/volvulus | 22 (4c) |
| | Hiatal hernia | 23 (4c) | C |
| Pyloric stenosis | Congenital | 24 (4c) | C |
| | | 25 (4b) |
| | | 26 (4c) |
| Chronic hypertrophic pyloric gastropathy | | 27 (4c) | C |
| Foreign body | | 28 (4c) |
| | | 29 (4a) |
| | | 30 (4c) |
| | | 31 (4c) |
| Dietary | | 32 (4b) | C |
| | | 33 (4c) |
| Infection/infestation | Canine parvovirus | 34 (1b) | A |
| | | 35 (1b) |
| Canine distemper virus | | 36 (4c) |
| Canine coronavirus | | 37 (4b) |
| Salmonellosis | | 38 (4c) |
| Campylobacteriosis | | 39 (4c) |
| Mycobacterial infection | | 40 (4c) |
| Fungal infection | | 41 (4c) |
| | | 42 (4a) |
| Hookworms/Roundworms | | 43 (4c) | C |
| Inflammatory bowel diseases | Eosinophilic | 44 (4a) | C |
| | Lymphoplasmacytic | | C |
| | Granulomatous | | C |

(Continued overleaf)
### Table 2. (continued)

| Process                  | Reference (LOE) | Overall evidence grade |
|--------------------------|-----------------|------------------------|
| Intestinal neoplasia     | 45 (4b)         | C                      |
|                          | 46 (4c)         |                         |
|                          | 47 (4b)         |                         |
|                          | 48 (4c)         |                         |
| Intussusception          | 49 (4b)         | C                      |
| Intestinal volvulus      | 50 (4c)         | C                      |
| Intestinal entrapment    | 51 (4c)         |                         |
| Motility disorders       |                  |                        |
| Dysautonomia             | 53 (4a)         | C                      |
| Localised autonomic dysfunction | 55 (4c) | C |

### Table 3. Non-gastrointestinal abdominal disease conditions associated with emesis in the dog

| Process                          | Reference (LOE) | Overall evidence grade |
|----------------------------------|-----------------|------------------------|
| Peritoneal neoplasia             | 59 (4c)         | C                      |
| Steatitis                        | 60 (4c)         | C                      |
| Peritonitis                      | Septic          |                         |
| Bile                             | 63 (4c)         | C                      |
| Urine                            | 64 (4b)         |                         |
| Idiopathic                       | 65 (4c)         | C                      |
| Hepatobiliary disease            | Neoplasia       | 66 (4c)                |
|                                  | Hepatitis/hepatopathy | 67 (4a)            |
|                                  | 68 (4c)         | C                      |
|                                  | 69 (4b)         |                         |
| Infectious                       | 70 (4a)         | C                      |
|                                  | 71 (4b)         |                         |
|                                  | 72 (4b)         |                         |
| Immune (?)                       | 73 (4c)         | D                      |
| Toxic                            | 74 (4c)         | C                      |
| Cholangiohepatitis/Cholangitis/Choledolithiasis | 76 (4c) | C |
| Gall bladder torsion/rupture     | 78 (4c)         | C                      |
| Lobe Torsion                     | 79 (4c)         | C                      |
| Abscess                          | 80 (4c)         | C                      |
| Splenic diseases                 | Torsion         | 81 (4c)                |
|                                  | Abscess         | 82 (4c)                |
|                                  | Infarction      | 83 (4c)                |
| Pancreatic diseases              | Neoplasia       | 84 (4a)                |
|                                  | Pancreatitis    | 85 (4a)                |
|                                  | Neoplasia       | 86 (4c)                |
|                                  | Phlegmon        | 87 (4c)                |
|                                  | Pseudocyst      | 87 (4c)                |
|                                  | 88 (4c)         |                         |
| Renal diseases                   | Abscess         | 89 (4c)                |
| Urogenital diseases              | Nephrolithiasis/Abscess | 90 (4c) |
|                                  | Neoplasia       | 91 (4c)                |
|                                  | Pyometritis     | 92 (4c)                |
|                                  | Endometritis    | 93 (4c)                |
|                                  | Urethro lithiasis | 94 (4b)          |

### CONSEQUENCES AND COMPLICATIONS OF EMESIS

Emesis is associated with signs of nausea (e.g., depression, salivation, lip licking, increased swallowing motions) and loss of appetite. Whilst, in most clinical situations, the consequences of the disease process per se and of emesis cannot be completely distinguished, persistent and severe emesis leads to loss of gastrointestinal fluid and electrolytes, with consequent dehydration, hypovolaemic shock, acid-base and electrolyte disturbances (e.g., metabolic acidosis/alkalosis, hypokalemia) which can be life-threatening (Boag and others 2005 [4a], Cornelius and Rawlings 1981 [4a]). Aspiration pneumonia can occur secondary to vomiting (Kogan and others 2006 [4a]). Persistent vomiting that prevents effective oral intake of food is likely to lead to protein-calorie malnutrition (see ‘Dietary management’). These concomitant problems must be assessed and treated appropriately as part of the clinical management of the dog with emesis. [OEG C].

### CLINICAL PRESENTATION AND INITIAL ASSESSMENT

Initial assessment of dogs with emesis should evaluate their general health condition (determination of the severity of the disease process) which will differentiate those in which no treatment is necessary, those which need to be treated symptomatically and those which need further examination or specific treatment. In addition the initial assessment may give clear indications of the underlying cause of the vomiting.

The initial assessment starts with the age, breed and gender of the dog. The age is important because some diseases are more common in young dogs, e.g., ingestion of foreign bodies, foreign body induced ileus (Capak and others 2001 [4a]), dietary indiscretion, infectious diseases, intussusception, chronic intestinal pseudo-obstruction (Johnson and others 2007 [4c]), and other diseases e.g. gastric neoplasia, are more common in older dogs (Gualtieri 1996 [4b], Gualtieri and others 1999 [3a], Sautter and Hanlon...
Table 4. Systemic disease conditions associated with emesis in the dog

| Process                        | Reference (LOE) | Overall evidence grade |
|--------------------------------|-----------------|------------------------|
| Metabolic                     |                 |                        |
| Uraemia                       | 95 (4c)         | C                      |
|                               | 96 (4a)         |                        |
|                               | 97 (4b)         |                        |
| Ketoacidosis                  | 98 (4a)         | C                      |
|                              |                 |                        |
| Hepatic encephalopathy       |                 | D                      |
|                              |                 |                        |
| Hypoadrenocorticism          | 19 (4c)         | C                      |
|                               | 99 (4b)         |                        |
|                               | 100 (4a)        |                        |
|                               | 101 (4c)        |                        |
|                               | 102 (4a)        |                        |
|                               |                 |                        |
| Hypercalcaemia                | 103 (4c)        | C                      |
|                               |                 |                        |
| Hypocalcaemia                 | 104 (4c)        | C                      |
|                              |                 |                        |
| Hypocobalaminaemia           | 105 (4c)        | C                      |
|                              |                 |                        |
| Hypokalaemia                  | 106 (4c)        | C                      |
|                               |                 |                        |
| Septicaemia                   | 107 (4b)        | C                      |
|                               |                 |                        |
| Hyperviscosity                | 108 (4b)        | C                      |
|                               |                 |                        |
| Ethylene glycol               | 109 (4c)        | C                      |
|                               |                 |                        |
| Toxics                        |                 | D                      |
|                               |                 |                        |
| Lead                          | 110 (5)         | D                      |
|                               |                 |                        |
| Apomorphine                   | 111 (1b)        | A                      |
|                               | 112 (1b)        | A                      |
|                               | 113 (1b)        | A                      |
|                               | 114 (1b)        | A                      |
| Many others                   |                 | D                      |
| Drug induced                  |                 |                        |
| Chemotherapeutics e.g.        | 115 (4b)        | A                      |
| cisplatin, methotrexate       |                 |                        |
|                               | 116 (1b)        | A                      |
|                               | 117 (1b)        | A                      |
|                               | 118 (4b)        | A                      |
|                               | 119 (1b)        | A                      |
| Digoxin                       | 120 (1b)        | A                      |
|                               | 121 (4c)        | A                      |
| Erythromycin                  | 122 (1b)        | A                      |
|                               | 123 (1b)        | A                      |
|                               | 124 (1b)        | A                      |
|                               | 125 (1b)        | A                      |
| Many others                   |                 | D                      |

Table 5. Nervous system disease conditions associated with emesis in the dog

| Process                        | Reference (LOE) | Overall evidence grade |
|--------------------------------|-----------------|------------------------|
| Trauma                         |                 | D                      |
| Hydrocephalus                  |                 | D                      |
| Space-occupying lesion         | 126 (4c)        | C                      |
|                               | 127 (4c)        |                        |
| Meningitis                     |                 | D                      |
| Encephalitis                   |                 | D                      |
| Motion sickness                | 128 (1b)        | B                      |
|                               | 129 (1b)        | B                      |
|                               | 130 (2b)        | B                      |
| Vestibular disease             |                 | D                      |
| Cerebellar disease             |                 | D                      |
| Visceral epilepsy              |                 | D                      |
| Sialadenosis(?)                | 131 (4c)        | C                      |

C. Elwood and others

1975 [4b]). Breed is an important consideration; Belgian shepherd dogs have a breed predisposition for gastric carcinoma (Scanziani and others 1991 [4c]), chronic hypertrophic pyloric gastropathy is seen more often in certain toy breeds (Bellennger and others 1990 [4c], Walter and others 1985 [4c]), and hypoadrenocorticism in the Nova Scotia Duck tolling retriever (Hughes and others 2007 [4b]). There are many more breed predispositions that can be mentioned. Some diseases also have a gender predilection e.g. hypoadrenocorticism is more commonly seen in female dogs (Kintzer and Peterson 1997 [3a]) and some diseases exclusively affect one gender (e.g. pyometra, prostatitis).

A full and complete history is essential for evaluation of a vomiting dog. Information which should be obtained is listed (Table 6). The most important distinction is that between vomiting and regurgitation, because their aetiologies are very different and this will direct specific diagnostic testing. Regurgitation is passive, with undigested food or saliva returned under gravity, whereas vomiting is a reflex, accompanied by signs of nausea, hypersalivation and activity of the abdominal musculature.

A thorough physical examination is required and should include assessment of features shown (Table 7). From the signalment, history and physical examination, the clinician should be able to identify criteria for concern which might indicate a need for immediate diagnostics investigation and/or therapy (Table 8). [OEG C].

DIAGNOSTIC APPROACH

The misnomer ‘acute gastritis’ is commonly used to describe a syndrome of acute and self limiting emesis. In almost all of these cases, however, gastric inflammation is not proven by histopathology. Gastritis is a frequently cited yet rarely confirmed diagnosis in cases of canine anorexia and emesis. Dogs with simple, mild, acute self limiting emesis do not need further work-up, and can be treated symptomatically. Many of these animals are not seriously ill, and may need no treatment. A recent study suggests 95% of dogs with emesis do not present to the veterinary surgeon (Hubbard and others 2007 [4a]). Even in
## Table 6. History taking for the dog with emesis

| A thorough history should be obtained during the initial assessment, including the following: | Example demonstrating the importance of this information | Reference (LOE) | Overall evidence grade |
|---|---|---|---|
| Onset and progression of signs | Sudden onset can suggest ingestion of foreign body or dietary indiscretion | 29 (4a) | C |
| Emesis or regurgitation | Regurgitation is seen in oesophageal disease | 132 (4b) | C |
| Relationship to eating | Vomiting > 10-12 hours after meal indicates delayed gastric emptying (outflow obstruction, motility disorder) | 30 (4c) | C |
| The frequency, volume and nature of vomitus, including the presence of any fresh or digested blood | Haematemesis is sometimes seen after use of NSAIDs or acute vomiting | 133 (4c) | |
| Whether or not there is any diarrhoea | Diarrhoea may suggest concurrent intestinal disease, but can be seen with other conditions e.g. pancreatitis | 139 (4b) | C |
| Presence and progression of weight loss | Weight loss suggests chronic disease, e.g. gastro-intestinal tumour | 144 (4a) | C |
| Appetite and ability to maintain nutritional status | Early enteral nutrition is important in recovery | 145 (3b) | B |
| Fluid intake (increased, decreased or normal) | Polydipsia is seen with pyometritis | 146 (4a) | C |
| Presence and nature of any abdominal pain | Abdominal pain can e.g. be seen in pancreatitis | 85 (4a) | C |
| Recent changes in diet or provocative changes, including recent or ongoing drug treatment and access to toxins or foreign bodies | Emesis can be seen as a side effect of many drugs. | 147 (4c) | A |
| Change in diet can cause vomiting | | 148 (4b) | |
| Severe exercise can cause gastritis. | | 150 (1b) | |
| Intoxication can cause vomiting e.g. ethylene glycol, grapes, *Bufo marinus* | | 151 (4b) | |
| Ingestion of foreign body is a cause of emesis | | 152 (4c) | C |
| Vaginal discharge can be seen in pyometritis | | 134 (4b) | |
| Reproductive status including recent seasons and presence of any vaginal discharge | Information on the reproductive status can suggest mucometra or closed cervix pyometra | 155 (4b) | C |
| Co-existing neurological signs suggest neurologic disease | | 156 (4c) | C |
| Presence of neurological signs e.g. head tilt, ataxia, nystagmus, altered behaviour or consciousness | Emesis associated with motion sickness | 128 (4c) | B |
| Presence of other signs suggestive of a systemic disease e.g. urinary tract signs (dysuria etc) | Urinary tract disorders can be associated with emesis | 158 (4b) | C |

In those cases where further investigation is considered necessary a variety of diagnostic tests may be indicated (Table 9). [OEG D]

### TREATMENT

A number of potential adverse effects of persistent emesis have already been detailed. Treatment of persistent emesis reduces suffering and prevents complications whilst a thorough investigation is undertaken to identify and, where possible, treat the underlying cause.

The decision to treat emesis or to wait and see if the problem resolves will depend on the circumstances in each individual case where the risk-benefit analysis of using a drug to prevent further emesis...
needs to be assessed (Hubbard and others 2007 [4a]). These authors showed that in 89% of dogs with signs of vomiting, signs resolved in less than two days. The clinician should judge the need for further investigation and treatment; a suggested approach is summarized in the algorithm (Figure 2). Emesis may be a desirable outcome following toxic ingestion, and antiemetics, especially where there is also a pro-kinetic effect, are not indicated where there is gastrointestinal obstruction. To minimise the risk of anti-emetics masking significant clinical signs it is important to initially identify those cases requiring further investigation and to ensure effective follow-up examinations are planned to reassess the progress of cases that are treated symptomatically. A risk benefit assessment should be made of the likely success of a particular drug in preventing and treating emesis versus the likelihood of the drug inducing adverse effects.

If the veterinarian considers initial treatment unnecessary or institutes non-specific, symptomatic management for suspected acute self-limiting vomiting, pet owners should be advised that, following initial assessment, there is no immediate need for a more specific diagnosis or treatment and that non-specific therapy is sufficient in many cases (Hubbard and others 2007 [4a]). They should be advised of the benefits and effects of therapy and of what outcome measures to monitor (see ‘Monitoring’ below). The use of an antiemetic drug should not delay any necessary investigation or treatment if deemed necessary by the clinician. Supportive care of the patient with emesis may include fluid and electrolyte therapy to correct or prevent dehydration and/or electrolyte and acid-base therapy. Though treating the symptom itself will often improve patient demeanour and comfort, it is no replacement for making a correct diagnosis. [OEG D].

### The ideal antiemetic

Antiemetics are used symptomatically to manage a clinical manifestation of a wide spectrum of different diseases. In many clinical situations e.g. uraemia, emesis may occur because of a combination of stimuli (central and peripheral). The relative importance of the different pathways may or may not be apparent from the clinical presentation or diagnosis. The ideal drug will, therefore, prevent both central and peripheral stimuli of the ‘vomiting centre’ (see section ‘Causes of vomiting’). In addition, because persistent and/or severe emesis can result in significant fluid loss and electrolyte disturbances, the ideal antiemetic drug should be without effect on the cardiovascular system since actions here can upset the delicate haemodynamic balance in a dehydrated patient. Furthermore, a drug with a very wide therapeutic index would be desirable, particularly as emesis can be associated with kidney and liver disease, two major organ systems involved in the clearance of drugs from the body. Drugs with narrow therapeutic indices would be unsafe to administer to dogs with significant kidney or liver dysfunction. In addition central nervous system side-effects, such as sedation, might be undesirable in drugs used treat emesis because changes in central nervous system (CNS) function may make diagnosis of the underlying cause of the emesis or assessment of the progression of the dog’s condition difficult and, potentially, predispose to adverse events such as aspiration. Finally, a lack of direct effects of an antiemetic on GI motility would be desirable in most cases, although a prokinetic effect may be beneficial in some conditions such as chronic gastritis.

It should be recognised that, because of the multiple inputs into the vomiting centre, the involvement of co-transmitters within a given pathway and the facilitatory actions of a number of neurotransmitters on each pathway, the holy grail of identifying one drug that inhibits all...
Emesis in dogs

Table 8. Criteria for concern in vomiting dogs

| A number of findings on initial consultation and examination might indicate a need for further investigation including: | Example demonstrating the importance of this information | Reference (LOE) | Overall evidence grade |
|---|---|---|---|
| **Very frequent acute emesis, vomiting large volumes (especially if food has been withheld), vomiting contents of a foetid nature** | Can be a sign of ileus, needing surgical intervention and symptomatic treatment | 58 (4c) 170 (4a) | C |
| **Chronicity (>3-4 weeks)** | Chronic emesis can indicate a not self limiting chronic gastrointestinal disease, which need specific diagnosis and treatment | 46 (4c) 171 (4c) 3 (4c) 44 (4a) 45 (4b) | C |
| **Marked weight loss/failure to thrive** | Marked weight loss is seen in dogs with neoplasia or chronic small intestinal disease. | 105 (4c) 44 (4a) 45 (4b) | C |
| **Marked malaise** | Significant malaise is rarely seen in trivial disease. | | D |
| **Marked abdominal pain** | Can indicate significant disease e.g. peritonitis, pancreatitis | 14 (4c) 142 (4a) | C |
| **Haematemesis and/or melaena** | Suggests gastro-intestinal ulceration or neoplasia | 172 (4c) 134 (4a) 173 (4a) | C |
| **Abdominal swelling/free fluid/palpable abdominal mass** | Protein losing enteropathy can lead to hypoalbuminemia and subsequent ascites | 174 (4b) 175 (4a) 176 (4c) 177 (4c) 178 (4c) | C |
| **Fever** | Might indicate peritonitis or other inflammatory/infectious disease | 63 (4b) 179 (4b) | C |
| **Associated polyuria/polydipsia** | Seen with pyometra, kidney failure, hypercalcaemia and hypoadrenocorticism | 96 (4a) 85 (4a) 103 (4c) 102 (4b) | C |
| **Severe dehydration/hypovolaemia/shock** | Needs fluid therapy | 99 (4b) | C |
| **Bradycardia (absolute or relative to volume status)** | Seen in hypoadrenocorticism | 100 (4a) 102 (4b) | C |
| **Other abnormal physical examination findings e.g., pale mucous membranes, jaundice, neurological signs, cardiac dysrhythmias etc.** | Pale mucous membranes and jaundice can be signs of haemolytic anaemia | 180 (4c) 77 (4c) 181 (4c) | C |
| Jaundice is seen in hepatobiliary diseases | Severe dermatologic signs together with emesis can indicate specific diseases | 46 (4c) 182 (4b) 183 (4c) | C |
| Persistence of emesis despite symptomatic therapy | Needs further work up | 184 (4a) | C |

Causes of emesis and nausea is never likely to be achieved. Figure 3 outlines the antiemetic drug target receptor distribution in relation to different arms of the vomiting reflex and Table 10 summarizes the properties of currently available antiemetic drug classes in veterinary medicine and the evidence for their usefulness in dogs, helping the clinician to select the drug whose profile best suits the individual patient.

Antiemetic treatment in practice

Most of the studies used to provide evidence for the statements made in table 10 are from experiments where the dog has been used as a model and emesis has been induced to determine the antiemetic’s efficacy. In clinical practice across Europe, a number of antiemetics may be used, such as metoclopramide (orally or by infusion), domperidone, ondansetron and acepromazine. Many of these drugs are in routine clinical use and are generally considered to be effective and useful, but few have been subjected to rigorous testing and there is a dearth of clinical evidence to support the efficacy of many of these antiemetic drugs under field conditions. A systematic search of the literature for ‘antiemetics AND dogs’ (limited to clinical trials) yielded 97 papers, only 5 of which were true clinical trials involving field cases in veterinary practice. Moore and others (1994 [1b]) examined the antiemetic effects of butorphanol and cyproheptadine in clinical cases of lymphoma receiving cisplatin and demonstrated butorphanol was moderately effective. Valverde and others (2004 [1b]) demonstrated the value of pre-treating with acepromazine in preventing opiate-induced emesis in dogs receiving opiates as part of a pre-anaesthetic protocol. The other three papers involved the neurokinin-1 (NK-1) receptor antagonist, maropitant. De La Puente-Redondo and others (2007a [1b]) conducted a clinical trial examining the ability of antiemetic drugs to arrest emesis due to medical conditions in dogs under field conditions. In both phases maropitant performed significantly better than metoclopramide, both in terms of a lower proportion of dogs that vomited after administration of the antiemetic and the number of emetic events.
| Diagnostic test                                      | Indication                                      | Information that is intended to be obtained                      | Reference (LOE) | Overall evidence grade |
|---------------------------------------------------|-------------------------------------------------|-----------------------------------------------------------------|-----------------|------------------------|
| Complete blood count                              | Criteria of concern (table 5)                   | Dehydration, Hemocoagulation, Leucopenia, Polycythaemia, Anaemia | 100 (4a)        | C                     |
| Total protein, albumin                            | Diarrhoea, ascites                              | Hypoproteinaemia                                                | 175 (4a)        | C                     |
| Liver enzymes, bile acids                         | Jaundice, chronic emesis                       | Hepatobiliary disease                                          | 168 (4b)        | C                     |
| Blood glucose                                     | Diarrhoea in toy breeds, seizures              | Hypoglycaemia                                                  | 187 (5)         | D                     |
| Calcium                                           | Polyuria/polydipsia                             | Hypercalcaemia, Hypocalcaemia                                   | 100 (4a)        | C                     |
| Pancratic enzymes, cPLI (ACTH) stimulation test   | Abdominal pain                                  | Pancreatitis                                                   | 188 (4b)        | C                     |
| Coombs' test                                      | Pale mucous membranes, jaundice                 | Immune-mediated haemolytic anaemia                              | 186 (4b)        | C                     |
| Lipid profile                                      | Parvoviral enteritis                            | Prognostic factor                                              | 190 (3b)        | B                     |
| Electrolytes                                      | Dehydration, dysrhythmias, bradyard, fluid therapy | Electroty disturbance in need correction by fluid therapy, Changes of hypoadrenocorticism | 100 (4a) 102 (4b) 160 (4a) | C       |
| Culture of bile                                    | Liver enzyme activity increases, abnormal gall bladder or gall bladder content on ultrasound | Bacterial cholecystis | 183 (4c) 77 (4c) | C       |
| Ultrasonography                                   | Abdominal mass, increases in liver enzyme activity, free fluid in abdomen | Hepatobiliary disease, Foreign bodies, Neoplasia, Urinary tract disorders, Muco-/pyometra, Pancreatitis | 77 (4c) 156 (4c) 158 (4c) 85 (4a), 79 (4c), 159 (4c), 31 (4c) 180 (4c), 191 (4b) | C       |
| Radiography                                        | Very frequent acute vomiting, vomiting large volumes (especially if food has been withheld), vomiting contents of a foetid nature | Foreign body, Gastric position and size, Peritonitis, ileus, Intestinal entrapment | 192 (4c) 52 (4c) 85 (4a) 193 (4c) 31 (4c) 191 (4b) | C       |
| Electrocardiography                                | Dysrhythmias, bradyard                         | Hyperkalaemia                                                  | 100 (4a)        | C                     |
| Computed tomography                               | Abdominal organomegaly, focal pain             | Evaluation of abdominal organs                                 | 194 (4c)        | C                     |
| Magnetic resonance imaging                        | Abdominal organomegaly, focal pain             | Evaluation of abdominal organs                                 | 195 (4b)        | C                     |
| Liver biopsy                                       | Increases in liver enzyme activity and/or bile acid concentration, abnormal appearance of liver on ultrasound | Hepatobiliary diseases | 177 (4c) 69 (4b) | C       |
| Endoscopy                                          | Ingestion of foreign body                      | Visualisation of mucosa, Gastric and intestinal biopses         | 29 (4a) 198 (4b) 44 (4a) | C       |
| Faecal examination                                | Diarrhoea                                      | Parasitic disease                                              | 199 (4a)        | C                     |
| Urinalysis                                         | Signs of urinary tract disease (dysuria, haematuria) | Urolithiasis, urinary tract inflammation and/or infection | 158 (4c) 159 (4c) | C       |
| Parvovirus antigen test                            | Diarrhoea, haematochezia                       | Parvoviral enteritis                                           | 200 (1b)        | A                     |
Emesis in dogs

FIG 2. An algorithm to guide the approach to the management of emesis in the dog. If the patient is initially treated symptomatically, re-examinations should be scheduled and the patient re-assessed for criteria of concern (see table 8) that might prompt further investigation. [OEG D]

recorded in those dogs that vomited. Vail and others (2007 [1b]) examined the effect of maropitant on frequency of emesis in clinical patients receiving cisplatin, given at a higher dose than in the study of Moore and others (1994 [1b]), and demonstrated that maropitant prevented emesis and also suggested efficacy to treat emesis in clinical patients receiving cisplatin, as evaluated by a visual analogue scale. The final clinical trial also involved maropitant and examined its ability to prevent motion sickness in dogs prone to this problem (Benchaoui and others 2007 [1b]). This was a large multicentre placebo controlled clinical trial which demonstrated that maropitant reduced the number of dogs vomiting on the journey when compared to placebo.

DIETARY MANAGEMENT

There are limited data to advise small animal clinicians on the optimal feeding strategy for vomiting patients. Two main scenarios should be considered, and will be approached separately. The first is a severely affected vomiting patient where hospitalisation is required; the second is a patient where vomiting is less severe and can be handled as an out-patient.

Vomiting patients requiring hospitalisation

In humans, there is a wealth of information supporting the use of enteral methods of feeding over parenteral nutrition. In a critical review by Zaloga (2006 [1b]), compared with parenteral nutrition (PN), the use of enteral nutrition (EN) improved survival, decreased infection rate, decreased bacterial translocation, enabled earlier discharge from hospital, and was more cost effective. However, a meta-analysis examining the benefits of either enteral nutrition or volitional nutritional support over nil per os strategies is more controversial, suggesting that, whereas from using volitional nutritional support in geriatric patients, most studies did not demonstrate a clear benefit (Koretz and others 2007 [1a]).

Numerous studies are available which detail the methodology, applications, benefits and complications of both EN (Abood and Buffington 1992 [4a]; Michel and Higgins 2006 [4b]) and PN (Lippert and others 1993 [4a]; Vander and Payne-James 2006 [4c]) in dogs. A complete discussion of this information is outside the scope of the current review, but broadly speaking, both techniques can provide benefit to hospitalised in-patients, but are associated with various complications. Most notably vomiting and other alimentary tract signs are a common complication of the enteral method of feeding (Abood and Buffington 1992 [4a]). Thus one potential benefit of controlling nausea and vomiting in companion animals is that it may enable enteral nutrition to be administered at an earlier opportunity and with lower associated morbidity. Data from clinical studies directly comparing EN and PN in dogs with alimentary tract disease are, however, extremely limited.

Experimental studies in dogs

Two experimental studies have assessed the effects of early EN on pancreatic pathological features and gut barrier function in dogs with experimental acute pancreatitis (Qin and others 2002 [2b], Xu and others 2006 [2b]). The conclusion from these studies was that EN is preferred over PN for cases of acute pancreatitis. Clinical studies are, however, recommended to determine applicability in this setting.

Clinical studies in dogs

One randomised, unblinded, clinical study has compared the effect of early enteral nutrition (EEN), versus food withholding, in cases with parvoviral enteritis whose signs included emesis (Mohr and others 2003 [2b]). The EEN group were fed with a standard critical care diet, via naso-oesophageal tube, commencing after 12 hours of hospitalisation; in contrast, food was withheld in the ‘nil per os’ (NPO) group until emesis had ceased. There was a trend towards improved survival in the EEN group, given that all EEN dogs survived whilst 13/15 NPO did. The EEN group also showed earlier
clinical improvement, with more rapid
(by 1 day) improvement in demeanour,
appetite, vomiting and diarrhoea. Further,
significant weight gain occurred in this
group, but did not in the NPO group,
since clinical improvement, with more rapid
improvement in other outcome measures.

A similar clinical study has assessed the
benefits of combined parenteral and oral
nutrition compared with parenteral nu-
trition alone, in young dogs with haem-
orrhagic gastroenteritis (Will and others
2007 [4c]). Such information suggests
that early enteral nutrition is of benefi t,
but should be interpreted with caution.

The remaining publications are either
review articles or pertain to single case re-
ports or small case series where nutritional
support is employed as a component of
therapy for patients with severe gastroin-
testinal signs (Aroch and others 1997
[4c], Holland 1996 [4c], Young and oth-
ers 2007 [4c]). Such information suggests
that early enteral nutrition is of benefi t,
but should be interpreted with caution.

MONITORING

When symptomatic management is in-
stituted, only the prescribed medications
diet recommended by veterinari-
yan should be administered and an ini-
tial limit of 24 hours of any anti-emetic
treatment should be advised to observe the pet closely and
to contact the veterinary surgeon as soon
as possible if there are any signs of deterio-
ration and/or the patient is getting worse,
with a view to arranging a re-examination.
They should be advised to re-present the patient after a maximum of 48 hours if
there is continued emesis or if there is no
improvement in other outcome measures.

Alternative outcome measures include ap-
petite (which may re
ect associated nau-
sea), general demeanour, and other associ-
ated clinical signs e.g. diarrhoea. It should
be stressed that the owners should return
more quickly if they are concerned. At re-
assessment, the clinician should repeat the
initial consultation and re-consider crite-
ria for further treatment and/or investiga-
tion as above. [OEG D].
Emesis in dogs

Table 10. Antiemetic drugs in dogs

| Drug group and drug doses | Receptor pharmacology | Pathways inhibited | Other actions (including adverse effects) | Side-effects and contraindications | Reference (LOE) | Overall evidence grade (anti-emetic action) |
|---------------------------|-----------------------|-------------------|-------------------------------------------|-----------------------------------|----------------|--------------------------------------|
| Phenothiazines: Acepromazine: 0.01-0.05 mg/kg i.m., s.c. 1-3 mg/kg p.o. Chlorpromazine: 0.5 mg/kg i.m., s.c. q6-8h | D<sub>2</sub> and H<sub>1</sub> receptor antagonists. Anti-cholinergic and anti-serotonergic actions (weaker) | Central emetogens (anti-D<sub>2</sub>); motion sickness (anti-H<sub>1</sub>) | Alpha<sub>2</sub> receptor antagonists | Pre-licensing safety studies not performed. Decreases blood pressure in dehydrated animals Anti-cholinergic side effects Movement disorders | 201 (3b) 202 (2c) 203 (1b) | B |
| Butyrophenones: Domperidone: 2.5 mg per animal q8h | D<sub>2</sub> antagonist | Central emetogenic pathway | Alpha<sub>2</sub> receptor antagonists | Pre-licensing safety studies not performed. Decreases blood pressure in dehydrated animals Sedative actions | 117 (2b) 112 (2b) | C |
| Metoclopramide: 0.2-0.5 mg/kg i.m., s.c., p.o. q6-8h or 1-2 mg/kg i.v. over 24 hours as slow constant rate infusion. | D<sub>2</sub> antagonist 5-HT<sub>3</sub> antagonist (weak) H<sub>1</sub> antagonist (weak) | Central emetogenic pathway (D<sub>2</sub> antagonism); some action versus peripheral emetogens Some effect vs. motion sickness (weak) At high doses reduces gastro-oesophageal reflux associated with anaesthesia and dopamine-induced inhibition of lower oesophageal sphincter tone | Variable prokinetic effect (peripheral) which may contribute to antiemetic action in some, but not all cases | Pre-licensing safety studies not performed. Increases detrusor muscle contractility reducing bladder capacity Movement disorders Extrapyramidal signs | 204 (2b) 205 (1b) 206 (1b) 207 (3b) 208 (1b) 209 (1b) 210 (2b) 211 (2b) 212 (2b) | B |
| Ondansetron: 0.5 mg/kg i.v. loading dose followed by 0.5 mg/kg/h infusion for 6 hours or 0.5-1 mg/kg p.o. q12-24 hours | 5-HT<sub>3</sub> selective antagonists | Works best versus acute peripheral emetogens (e.g. chemical irritants to the gut - cisplatin causing degranulation of enterochromaffin cells and 5-HT release). Also effective vs. radiation-induced emesis. Represented a major breakthrough in preventing acute (but not delayed) emesis associated with cancer chemotherapy, Relatively ineffective versus central emetic stimuli | 5-HT<sub>3</sub> receptors are involved in regulating GI motility so blockade could disrupt these physiological functions 5-HT<sub>3</sub> receptors involved in sleep-induced apnoea; ondansetron inhibits this phenomenon | Pre-licensing safety studies not performed. Dose escalation studies in for human toxicity suggests safe at 100 times normal dose Extrapyramidal signs | 213 (2b) 214 (2b) 215 (2b) 216 (1b) 217 (3b) 218 (2b) 219 (2b) 220 (3b) 221 (1b) 222 (2b) | B |
| Maropitant: standard emesis 1mg/kg s.c. q24h. For prevention of motion sickness up to 8mg/kg p.o. q24h for maximum of 2 days | NK<sub>1</sub> receptor antagonists (highly selective) | Work well versus both peripheral and central emetogens. Higher dose required to prevent motion sickness Anti-nausea effect more difficult to measure and assess clinically | Binds to voltage dependent calcium channels at very high concentrations; significant inhibition only seen at concentrations 77 times peak plasma concentrations when dosed at 8mg/kg (bradycardia, decrease in BP) | Use with caution in cardiac disease, hepatic disease, hypoproteinaemia and when administering other highly protein bound drugs.* | 128 (1b) 129 (1b) 206 (1b) 119 (1b) 114 (1b) 223 (1b) 224 (2b) | A |

*Safety of maropitant in lactating/pregnant bitches and in dogs <18 weeks old is not established. US Food and Drug Administration licence contraindicates use in these groups and where GI obstruction or toxic ingestion suspected. European Medicines Agency (EMEA) Summary of Product Characteristics advises risk/benefit assessment by veterinarian in these situations.
Cancer Chemotherapy and Emesis

Nausea and vomiting are among the most feared complications of chemotherapy and the owner of an animal with cancer is often more concerned about the well-being of the patient than about the success of a treatment. Nausea and vomiting in an animal with cancer can be explained by three main mechanisms:

i. The localisation of the tumour: gastrointestinal (oesophagus, stomach, intestine), liver or pancreas (Sullivan and others 1987 [4b], Wang and others 2002 [4c]).

ii. Associated paraneoplastic syndromes (e.g. mastocytoma, APUDoma) (O’Keefe and others 1987 [4c], Zerbe and others 1989 [4c]).

iii. The treatment (surgery, radiotherapy and, most importantly, chemotherapy) (Gylys and others 1979 [2b]).

Here, we will only discuss nausea and vomiting originating from chemotherapy in dogs. Treatment has changed over time because of better understanding of the pathophysiology, more insight in the relationship between the different drugs used in cancer chemotherapy and, finally, the development of new drugs. [OEG C].

Pathophysiology and origin of vomiting

Three types of vomiting due to cancer chemotherapy can be distinguished:

i. Anticipated vomiting, which is frequently seen in human medicine but is very rare in our domestic animals. It corresponds to a Pavlov-like type of reflex and is dependent on the memory (e.g. visual stimuli, stimuli by odour related to the clinic, the hospitalisation or personnel). In this type of vomiting it is important to treat with an antiemetic before chemotherapy to avoid activation of the reflex. Whilst there is evidence of nausea and emesis as a conditioned response in humans receiving chemotherapy, there is no published evidence for these mechanisms in dogs.

ii. Acute vomiting, which can manifest during the first 24 hours after chemotherapy and can be caused by either central (chemoreceptor trigger zone) or peripheral stimulation. This is the predominant mode of action of cytotoxic drugs.

iii. Delayed vomiting which starts between 1 and 5 days after treatment (Fukui and Yamamoto 1999 [1b]). Its mechanism is complex and multi-factorial. It may be attributed to a reduction in intestinal motility or to alteration of the intestinal mucosa and its release of hormones (serotonin, norepinephrine) or to a reduction of urinary cortisol excretion. It can also be the result of accumulation of metabolites of cytotoxic agents (especially those derived from platinum).

[OEG C].

Classification of the risks of emesis

The risk of and severity of emesis seen varies according to the cytotoxic agent used and may be classified as heavy, moderate, weak and minimal (Jordan and others 2005 [3a]) (Table 11).

Prevention and treatment of vomiting in the dog

Whilst, in human medicine, there are accepted protocols for the management of chemotherapy induced nausea and vomiting, these have yet to be established in veterinary medicine. Until recently the antiemetics commonly used to treat emesis associated with chemotherapy in canine medicine were metoclopramide and ondansetron. Controlled clinical trials of these drugs are, however, scarce, and no studies have demonstrated their effectiveness in placebo controlled trials in tumour bearing dogs. Other drugs have been investigated; butorphanol was moderately effective in clinical cases of lymphoma receiving cisplatin and ginger extracts have also been tested against cisplatin-induced emesis in dogs, with suggested benefit (Moore and others 1994 [1b], Sharma and others 1997 [2b]). In the 1990s, the discovery of the anti-serotoninergic (e.g. ondansetron) led to improved prevention of acute emesis but delayed vomiting was still frequently seen (Sagrada and others 1991 [1b]). A small experimental trial of cisplatin induced emesis in dogs showed that pre-treatment with both ondansetron and granisetron could significantly inhibit vomiting (Topal and others 2005 [3b]). Recently, the NK-1 antagonist, maropitant, has proven its efficacy in the prevention of emesis after treatment with cisplatin in the clinic (De La Puente-Redondo and others 2007b [1b], Vail and others 2007 [1b]). [OEG A].

Conclusion

Undertaking this extensive review of the literature relating to the aetiology, diagnosis and management of emesis in dogs has emphasised how much of accepted practice is based on little peer-reviewed evidence, with much extrapolation from human medicine and application of expert experience and opinion. This review highlights those important clinical questions of genuine uncertainty and should provide a basis to direct future clinical studies.
Emesis in dogs

Acknowledgements
The authors would like to acknowledge the help and support of Pfizer Animal Health, the manufacturers of maropitant.

References

Carpen erson, D. O. & Briggs, D. B. (1983) Insulin excretion of area postrema neurons in dogs. Journal of Neurophysiology 49, 1391-1396.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpen erson, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.

Carpenter, D. O., Briggs, D. B. & Strominger, N. (1986) A selective neurokinin 1 receptor antagonist, in Species Differences in Pathophysiology of Esophageal Motility. American Journal of Neuroro 85, 529-536.
intestinal protein loss, and outcome in dogs with severe paroviral enteritis. Journal of Veterinary Internal Medicine 17, 791-798

Moselle, A. S., Ragsdale, W. M., Bos, J., L’Héritier, D. A. & Dennis, R. A. (1994) Evaluation of butorphanol and cyproheptadine for prevention of cisplatin induced vomiting in dogs. Journal of the American Veterinary Medical Association 205, 443-444

OKADA, D. A., COUTO, C. G., BRUNE-SCHWARTZ, C. & JACOB, R. M. (1987) Systemic mastocytosis in 16 dogs. Journal of Veterinary Internal Medicine 1, 242-246

Ong, T., Moe, T., Yasumasa, M., Fukuji, N. & Fufuda, H. (2007) Similitude of the neural circuit for the terminal phase of the vomitogenic reflex and the autonomic nervous system. Veterinary Medicine 32, 371-376

PASQUALINI, M. & OLIVI, C. R. (2002) Scirrhous gastroenteritis in a dog. Journal of Veterinary Internal Medicine 16, 157-161

Watanabe, T., Hashimoto, Y., Hara, M., Maeta, T. & Iijima, K. (2002) Acute digestive tract obstruction in the dog. Journal of Veterinary Medicine A 49, 805-810

Watanabe, S. C. & Chin, H. I. (1995) Experimental motion sickness in dogs: functional importance of chemo-ceptive emitter trigger zone. American Journal of Physiology 278, 111-116

Wall, K. E., Nest, E. J. & Zlotek, J. (2005) Early enteral nutrition in young infants suffering from haemorrhagic gastroenteritis. Journal of Veterinary medicine. A, Physiology, patholgy, clinical medicine 52, 371-376

Xu, G. F., Liu, S., Gao, J. L., Z. S. & Geis, Y. F. (2006) Effect of exogenous chemokine supports on maintenance of integrity of intestinal mucosal barrier in severe acute pancreatitis in dogs. Chinese Medicine 37, 236-242

Young, B. C., Stron, M. A., Prasse, J. E. & Barton, L. J. (2002) Effect of early enteral nutrition on pancreatic pathological features and gut barrier function in dogs with acute pancreatitis. Clinical Nutrition 21, 469-473

Sagawa, A., Torizumi, H., Morii, S., Shinoda, M., Morii, M. & Hori, M. (1995) Effect of human interferon gamma on colon cancer cell line. Cancer chemotherapy and pharmacology 20, 17-19

Shakir, B. K. (2001) Rationale for early feeding in 18 Journal of Small Animal Practice Vol 51 January 2010 © 2010 British Small Animal Veterinary Association

Wang, F. I., Lee, J. J., Liu, C. H., Pang, V. F., Chang, P. H. & Qin, H. L., Su, Z. D., Hu, L. G., Ding, Z. X. & Lin, Q. (2004) Effects of acepromazine on the incidence of vomiting induced by duodenal distension in dogs. Veterinary Medicine 49, 264-267

Valverde, A., Cantwell, S., Hernandez, J. & Brotherson, C. (2008) Similarities of the neuronal circuit for fictive vomiting between ferrets and dogs. Journal of Neuroscience 29, 157-161

Steinberg, M., Drezeg, R. R., Thomsen, J. & Deita, G. (1995) Primary gastrointestinal lymphosarcoma with epitheliotropic in three Shar-pei and one boxer dog. Veterinary Quarterly 221, 426-432

Kamei, D. R. (1996) Managing gastrointestinal complications of uremia. The Veterinary Clinics of North America: Small Animal Practice 26, 1287-1292

Hafpe, R. P., Van, G. D., Lamers, C. B., Van Tonder, J., Reveiz, J. F. & Larson, L. I. (1980) Zollinger-Ellson syndrome in three dogs. Veterinary Quarterly 17, 177-186

Swih, D. H. (1988) Gastrintestinal (Zollinger-Ellison Syndrome) in the Dog and cat. Canadian Veterinary Journal 39, 448-452

Zere, C. E., Boosinger, T. R., Gahai, J. H., Pletcher, J. M. & O’Donnol, T. M. (1989) Pancreatic polypeptide and insulin-secreting tumor in a dog with duodenal ulcers and hypoglycemic gastropathy. Journal of Veterinary Internal Medicine 3, 178-182

APPENDIX 1

References to tables

1. Ofno Centre for Evidence Based Medicine (2003) 1.1. A. Elwood and others 120

2. L. J. (2007) Toxic pneumonitis caused by ingesting hydrocarbon waterproofing spray in two dogs. Journal of Veterinary Internal Medicine 21, 1169-1172

3. Van der Graaf, J., Hafpe, R. P. & Wiedenmann, W. T. (1976) A boxer dog with chronic, hypereosinophilic gastritis resembling Menetrier’s disease in man. Veterinary Quarterly 17, 172-185

4. Van der Graaf, J., Hafpe, R. P. (1989) Follow-up studies on peroral gastric biopsies and necropsy in vomiting dogs. Canadian Journal of Veterinary Research 53, 468-472

5. Harpold, L., Linnen, J., Sutter, S. & Kraninger, M. (1972) Severe paroviral enteritis. Journal of the American Veterinary Medical Association 152, 1767-1774

6. Lin, S. M., Adams, R. B. & Wang, W. L. (2003) Triple antimicrobial therapy and acid suppression in dogs with chronic vomiting and gastric Helicobacter pylori. Journal of Veterinary Internal Medicine 17, 1185-1192

7. Winberg, B., Storl, A., Dietz, H. H., Ullberg, T., Gross, E., Uhl, M. E., Granath, S., P. O. Olsson, J., Frisen, S., Chang, Y. F. & Simpson, K. W. (2005) Quantitative assessment of inflammatory and immune responses in dogs with gastric and their relationship to Helicobacter sp. infection. Journal of Veterinary Internal Medicine 19, 4-14

8. Sullik, M., Lee, R., Bae, E. W., Na, A. S. & McCandlish, I. A. (2008) A study of 33 cases of gastric carcinoma in dogs. Veterinary Record 162, 94-94

9. Eger, P. A., Connell, K. K., Rain, A. M. & Seiler, B. A. (2003) Gastric outflow obstruction after ingestion of wood glue in a dog. Journal of the American Animal Hospitals Association 39, 47-51

C. Elsidos and others

Journal of Small Animal Practice • Vol 51 • January 2010 • © 2010 British Small Animal Veterinary Association
phy and contrast enhanced computed tomogra-
phy to evaluate acute necrotizing pancreatitis in
two dogs. Veterinary Radiology and Ultrasound
72, 172-79
88. Smith, S. A. & Biller, D. S. (1998) Resolution of a pancreatic pseudocyst in a dog following percutaneous ultrasound guided-guided aspiration. Journal of the American Animal Hospital Asso-
ciation 34, 353-56
89. Slack, S. K., Lantz, G. C., Nelson, R. W. & Kac-
zirski, E. A. (1988) Pancreatic abscesses in dogs: six (1984-1986). Journal of the American Animal Veterinary Medical Association 193, 1104-
1108
90. Aziz, L., Laizé, F. G., Beza, E., Sei, J. & Souè, M. (2004) Left peripancreatic abscess associated with nephrolithiasis and bladder calculus in a bitch. Vet-
erinary Record 154, 562-65
91. Dempster, A. G., Delamont, B., Macniss, A. W. & Wade, E. G. (2003) Regression of retinoblastoma in a dog after dessication with photodynamic therapy. Veterinary Record 154, 741-10
92. Veillet, G., Slavenberg, R. J. & Geuens, B. (1977) Multiple myeloma, IgA, plasmacytoma and serum hyper viscosity in a dog. International Archives of Allergy and Applied Immunology 55, 537-43
93. Konanyw, D. F. (1976) Lead poisoning in dogs at the University of Pennsylvania Veterinary Hospital. Journal of American Veterinary Medical Association 168, 428-432
94. Thamm, A., Ganser, G. F. & Moser, K. (1984) Clinico-pathologic findings in dogs and cats with ethylene glycol intoxication. Journal of the American Veterinary Medical Association 184, 37-41
95. Kamphans, M., Sacht, E. & Blankert, D. (2003) Ethanol absorption from the intestine of dogs; apples by a dog. Veterinary and human toxico-
logy 43, 349-50
96. Schenck, M. F., Healy, J. S., Christensen, T. M. & Kuff, D. F. (1997) Chocolate poisoning in dogs. Veterinary and human toxico-
logy 44, 1181-85
97. Knu, K. S. & Kuo, O. (2005) Cystic endometrial hyperplasia and endometritis in a dog following prolonged treatment of medroxyprogester-
one acetate. Journal of Veterinary Science 6, 115-116
98. Hume, D. Z., Drobatz, K. J. & HESS, R. S. (2006) Gastric relaxation and vomiting by apomor-
phine, morphine, and fentanyl in the conscious dog. European Journal of Pharmacology 541, 407-410
99. Fiore, J. F., Yoon, C. S., Rosen, M. F. & Goldberg, L. I. (1998) Prevention of apomorphine- or cisplatin-induced emesis in the dog by a com-
bination of methylxanthine and morphine. Cancer chemotherapy and pharmacology 42, 287-291
100. Letzring, R. A., Willens, J. L. & Bogart, M. G. (1981) Gastric relaxation and vomiting by ap-
omorphine, morphine, and fentanyl in the conscious dog. European Journal of Pharmacology 71, 28
101. Uebersfelder, K. M., Koss, M. & agony, K. (2001) Effect of apomorphine on peripheral venous gastrin and insulin levels in conscious dogs. Acta Physiologica Scandinavica 121, 155-160
102. Segal, H. S., Ramsey, D. S., Brouer, J. F., Eagleston, J. L., Shain, M. H. & Clemence, R. G. (2008) Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. Journal Of Veterinary Pharmacology and Therapeutics 31, 130-137
103. Krank, D. W., Richardson, R. C., Boney, P. L. & Hanson, K. (1998) Cisplatin therapy in 41 dogs with malignant tumors. Journal of Veterinary Internal Medicine 2, 41-46
104. Hino, N. & Yamagishi, K. (1999) Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemo-
therapy. European Journal of Pharmacology 372, 261-267
105. Goyco, J. A., Dohle, R. M. & Bateman, J. P. (1979) Antagonism of a cisplatin induced emesis in dogs. Research Communications in Chemical Pathology and Pharmacology 23, 61-68
106. Oughte, G. K., Moore, A. S. & Curtis, C. R. (1989) Evaluation of cisplatin-induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987). Journal of the American Veterinary Medical Association 159, 1399-1403
107. De la Guardia, A., Aguirre, R. J. & Armelin, G. C. (2007) Effect of maropitant for treatment and prevention of emesis caused by intravenous injection of cisplatin in dogs. American Journal of Veterinary Research 68, 48-56
108. Goto, G. B., Schenck, P. G. & Asdell, F. M. (1982) Effect of digoxin and amino sugar cardiac gly-
cosides. Veterinary Research Communication 6, 219-224
109. Hult, E. G., Steffen, E. F. & Wall, A. (1992) Effects of erythromycin in the dog upper gas-
trointestinal tract. American Journal of Physiology 263, G52-69
110. Ziv, M., Sattu, T., Naman, M., Inoue, M. & Mitshu-
aka, Y. (1984) Gastrointestinal motor stimulat-
ing activity of macrodol 3060 and analysis of their side effects on the canine gastrointestinal motility in anesthetized dogs. Drugs.
111. Foss, J. F., Yuan, C. S., Roizen, M. F. & Goldberg, A. F. & Le Coultre, R. A. (1992) Intracra-

cial meningioma with pulmonary metastasis in three dogs. Veterinary Quarterly 29, 136-202
112. Zani, F. A. & Hanes, L. A. (1980) Choleiurus tarsus.
114. Frenkel, J., Cribb, R. A. & Chin, H. X. (1994) Experiment-

tal motion sickness in dogs; functional impair-

tance of chemoceptive emetic trigger zone.
115. Schenker, J., Maciak, A., Tasker, S. E., Madd, J. W. & Mayan, I. G. (2000) Idiopathic pheno-


